Lördag 12 Juli | 11:16:18 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-20 08:00 Kvartalsrapport 2025-Q3
2025-08-28 08:00 Kvartalsrapport 2025-Q2
2025-05-30 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2025-05-28 - Årsstämma
2025-05-28 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-05-16 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2024-05-15 - Årsstämma
2024-02-27 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-30 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2023-05-29 - Årsstämma
2023-05-29 - Kvartalsrapport 2023-Q1
2023-03-13 - Bokslutskommuniké 2022
2023-01-09 - Extra Bolagsstämma 2022
2022-11-28 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2022-06-01 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-22 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-18 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2021-05-18 - Kvartalsrapport 2021-Q1
2021-05-17 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-28 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-28 - Bokslutskommuniké 2018
2018-11-29 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-09 - Kvartalsrapport 2017-Q3
2017-10-06 - Extra Bolagsstämma 2017
2017-08-31 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2017-05-11 - Årsstämma
2017-05-11 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016
2016-10-27 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-06-09 - Extra Bolagsstämma 2016
2016-04-22 - Årsstämma
2016-04-22 - Kvartalsrapport 2016-Q1
2016-04-21 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2016-02-10 - Bokslutskommuniké 2015
2015-10-29 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-04-22 - X-dag ordinarie utdelning LIDDS 0.00 SEK
2015-04-21 - Årsstämma
2015-04-21 - Kvartalsrapport 2015-Q1
2015-02-20 - Bokslutskommuniké 2014
2014-11-11 - Kvartalsrapport 2014-Q3
2014-08-21 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
LIDDS är ett läkemedelsbolag. Bolaget utvecklar läkemedelsprodukter baserade på en patentskyddad och kliniskt testad drug delivery-teknologi. Egenskaperna hos produkterna utgör grunden för LIDDS teknologiplattform för utveckling av injicerbara läkemedelsprodukter. LIDDS är förkortningen för Local Intelligent Drug Delivery System och bolaget har sitt huvudkontor i Uppsala.
2022-02-17 16:00:00

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the company will host a Capital Markets Day on March 9, 2022, for investors, analysts and media. The presentation will be held in English.

The Capital Markets Day is a hybrid event. Participants are welcome to participate either physically, at the Redeye office, Mäster Samuelsgatan 42, 10th floor, Stockholm, Sweden, or digitally.

The meeting is held between 15.00-18.00 CET on 9 March 2022 and includes an update on LIDDS operations, new long-term strategy, and its pipeline. The event will include presentations from LIDDS management team and a Q&A session with the opportunity to ask questions.

LIDDS will be represented by Nina Herne, CEO, Jan Törnell, Chairman of the Board, Johan Harmenberg, CMO, Jenni Björnulfson, CFO and Mattew Lindon, CSO. The presentation will be held in English and will also be available on the company website, www.liddspharma.com after the event.

Registration for the Capital Markets Day is made by emailing info@liddspharma.com. The last day to register is 7 March 2022. No pre-registration is required to watch the webcast. A link to follow the Capital Markets Day digitally and the full program for the Capital Markets Day will be published prior to the event on the company website.

LIDDS processes the personal data that you provide in your notification in accordance with our Privacy policy. Throughout the event, local Covid-19-related restrictions will be adhered to. For that reason, the event will turn wholly digital if necessary.

For more information, please contact:

Jenni Björnulfson, CFO and Head of IR, Phone: +46 (0)708 553805, email: jenni.bjornulfson@liddspharma.com.

The information was submitted for publication, through the agency of the aforementioned contact person, on February 17, 2022 at 16.00 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, certifiedadviser@redeye.se, +46 (0)8 121 576 90, is a certified adviser to LIDDS.  For more information, please visit www.liddspharma.com.